Home › Funds › ANDERSON HOAGLAND & CO › VRTX

ANDERSON HOAGLAND & CO position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

ANDERSON HOAGLAND & CO reported holding 15,734 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$8.4M, representing 0.64% of its reported portfolio and ranking #42 among its reported holdings. ANDERSON HOAGLAND & CO has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)15.73K sh
Reported value held$8.42M
Portfolio Weight0.64%
First reportedQ4 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How ANDERSON HOAGLAND & CO's VRTX position evolved

ANDERSON HOAGLAND & CO first disclosed a stake in VRTX in Q4 2023 at 16,674 shares (US$7.3M). The position peaked in Q2 2024 at 21,236 shares, worth US$10.3M. Across 12 filings, ANDERSON HOAGLAND & CO increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 15,734 shares valued at US$8.4M. Notable position changes include a 27% increase in Q1 2024 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 16.67K $7.29M New
Q1 2024 21.17K $8.42M Add
Q2 2024 21.24K $10.32M Hold
Q3 2024 21.26K $9.68M Hold
Q4 2024 21.18K $8.94M Hold
Q1 2025 19.82K $9.36M Reduce
Q2 2025 19.65K $8.75M Reduce
Q3 2025 15.77K $6.17M Reduce
Q4 2025 15.73K $7.13M Hold
Q1 2026 15.73K $7.03M Hold
Q2 2026 15.73K $7.82M Hold
Q3 2026 15.73K $8.42M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has ANDERSON HOAGLAND & CO held VRTX?

ANDERSON HOAGLAND & CO has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is ANDERSON HOAGLAND & CO's current position in VRTX?

As of Q3 2026, ANDERSON HOAGLAND & CO holds 15.73K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $8.42M, representing 0.64% of its reported portfolio and ranking #42.

Has ANDERSON HOAGLAND & CO been buying or selling VRTX?

In the latest 13F filing (Q3 2026), ANDERSON HOAGLAND & CO held unchanged its position in VRTX. The position peaked in Q2 2024 at 21.24K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.